These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11682992)

  • 1. Nationwide study seeks patients to investigate whether women respond differently to HIV treatment than men.
    Women Alive; 2000; ():5. PubMed ID: 11682992
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender, ethnicity, and clinical trials.
    Jefferys R
    Women Alive; 2001; ():2-3, 16-7. PubMed ID: 11683006
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical study on treatment of HIV infected persons based on viral load detection and CD4+ T lymphocyte counting].
    Lin X; Xu L; Feng Y; Li J; Pei L; Shen T; Shao Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):211-4. PubMed ID: 12665921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women and non-whites new to HAART respond similarly to men and whites.
    AIDS Patient Care STDS; 2008 Sep; 22(9):762. PubMed ID: 18802978
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment interruption: study found poor result for highly treated, highly resistant patients.
    James JS
    AIDS Treat News; 2003 Sep; (394):7-8. PubMed ID: 14669730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The feminization of an epidemic. Women and HIV in the United States.
    Iobst S; Gandhi M
    Posit Aware; 2009; 20(4):34-9. PubMed ID: 19653375
    [No Abstract]   [Full Text] [Related]  

  • 10. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral rounds. CD4 count 423, viral load 12,000: time to treat anyway?
    Hodder S; Frank I
    AIDS Clin Care; 2006 Jun; 18(6):59-60. PubMed ID: 16791955
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. A warning about high viral loads.
    TreatmentUpdate; 2003; 15(7):1-2. PubMed ID: 17216865
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV agents. Is FOTO a treatment interruption that works?
    TreatmentUpdate; 2005; 17(5):10-1. PubMed ID: 17219661
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-HIV agents. Rescue therapy.
    TreatmentUpdate; 2000 Mar; 12(2):5-6. PubMed ID: 12125620
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-HIV agents. Different effects of nukes in men and women.
    TreatmentUpdate; 2000 Sep; 12(6):1-2. PubMed ID: 12132458
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex, gender and HIV.
    Proj Inf Perspect; 2003 Oct; (36):15-6. PubMed ID: 14696572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response.
    Kofoed K; Gerstoft J; Mathiesen LR; Benfield T
    Sex Transm Dis; 2006 Mar; 33(3):143-8. PubMed ID: 16505739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
    Collazos J; Asensi V; Cartón JA
    AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.